Patents Assigned to Rhodes Technologies
-
Publication number: 20240109907Abstract: The application is directed to an efficient process for crystallizing nalmefene hydrochloride in a hydrated form from an aqueous hydrochloric acid solution (or a mixture) with a high yield.Type: ApplicationFiled: January 27, 2022Publication date: April 4, 2024Applicant: RHODES TECHNOLOGIESInventor: C. Frederick M. HUNTLEY
-
Patent number: 11845759Abstract: This invention relates to novel opioid derivatives of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R3, R4 and Z are as defined herein in the disclosure. The invention also relates to the use of such compounds for the treatment or prevention of, for example, pain.Type: GrantFiled: February 22, 2019Date of Patent: December 19, 2023Assignee: RHODES TECHNOLOGIESInventors: Ping Chang, Raymond Glowaky, Michael David Rogers
-
Publication number: 20230398073Abstract: The invention provides emulsion compositions comprising at least one cannabinoid compound, and methods for making the same. The emulsion compositions are stable, well tolerated and are capable of delivering therapeutically effective amounts of cannabiniods to target sites, including sites on the surface of and/or within an eye. Also provided are methods of using the compositions to provide ocular neuroprotection and/or to treat ophthalmic conditions such as glaucoma.Type: ApplicationFiled: August 22, 2023Publication date: December 14, 2023Applicant: Rhodes TechnologiesInventors: Ping CHANG, Zhenze Hu, Yuanyuan TAO
-
Publication number: 20230399334Abstract: The application is directed to a process of purifying noroxymorphone by preparing and isolating noroxymorphone bisulfite adduct and regenerating purified noroxymorphone from noroxymorphone bisulfite adduct. The application is also directed to a compound represented by the Formula I, described herein, or a hydrate or zwitterion thereof, and a crystalline form of noroxymorphone bisulfite adduct monohydrate.Type: ApplicationFiled: November 2, 2021Publication date: December 14, 2023Applicant: RHODES TECHNOLOGIESInventor: C. Frederick M. HUNTLEY
-
Publication number: 20230365578Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: ApplicationFiled: June 7, 2023Publication date: November 16, 2023Applicants: Purdue Pharma L.P., Purdue Pharmaceuticals L.P., Rhodes TechnologiesInventors: Robert CHAPMAN, Lonn S. RIDER, Qi HONG, Donald KYLE, Robert KUPPER
-
Patent number: 11786463Abstract: The invention provides emulsion compositions comprising at least one cannabinoid compound, and methods for making the same. The emulsion compositions are stable, well tolerated and are capable of delivering therapeutically effective amounts of cannabiniods to target sites, including sites on the surface of and/or within an eye. Also provided are methods of using the compositions to provide ocular neuroprotection and/or to treat ophthalmic conditions such as glaucoma.Type: GrantFiled: August 10, 2018Date of Patent: October 17, 2023Assignee: Rhodes TechnologiesInventors: Ping Chang, Zhenze Hu, Yuanyuan Tao
-
Patent number: 11773107Abstract: This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R1 is H or CH3, R2 is H or OH, n is 0, 1, 2 or 3, R3 and R4 are independently H or optionally substituted C1-C4 alkyl, or when n is 0, then R3 and R4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C1-C4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.Type: GrantFiled: March 13, 2020Date of Patent: October 3, 2023Assignee: Rhodes TechnologiesInventors: Robert J. Kupper, Raymond C. Glowaky
-
Patent number: 11731979Abstract: This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R1 is H or CH3, R2 is H or OH, n is 0, 1, 2 or 3, R3 and R4 are independently H or optionally substituted C1-C4 alkyl, or when n is 0, then R3 and R4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C1-C4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.Type: GrantFiled: August 20, 2021Date of Patent: August 22, 2023Assignee: Rhodes TechnologiesInventors: Robert J. Kupper, Raymond C. Glowaky
-
Publication number: 20230233635Abstract: The present invention provides pharmaceutical compositions and methods for use and manufacture thereof. The pharmaceutical compositions comprise a therapeutically effective amount of a cannabinoid or a pharmaceutically acceptable salt or solvate thereof and an amphiphilic copolymer comprising at least one hydrophilic component and at least one hydrophobic component. The cannabinoid is encapsulated in the amphiphilic copolymer, and the composition is suitable for intranasal or inhalation delivery.Type: ApplicationFiled: May 26, 2021Publication date: July 27, 2023Applicants: RHODES TECHNOLOGIES, UNIVERSITY OF SOUTH FLORIDAInventors: Chuanhai CAO, Ping CHANG
-
Publication number: 20230159548Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: ApplicationFiled: July 11, 2022Publication date: May 25, 2023Applicants: Purdue Pharma L.P., Purdue Pharmaceuticals L.P., Rhodes TechnologiesInventors: Robert CHAPMAN, Lonn S. RIDER, Qi HONG, Donald KYLE, Robert KUPPER
-
Publication number: 20230130617Abstract: Compounds and compositions for use as starting materials or intermediate materials in the preparation of opioids including, e.g., oxymorphone base and/or an oxymorphone salt; processes for preparing these compounds and compositions; uses of these compounds and compositions in the preparation of APIs and pharmaceutical dosage forms; and uses of said APIs and pharma ceutical dosage forms in the treatment of medical conditions.Type: ApplicationFiled: September 21, 2022Publication date: April 27, 2023Applicant: RHODES TECHNOLOGIESInventors: Stuart James GEBBIE, Joshua R. GIGUERE, Keith MCCARTHY, Lonn S. RIDER
-
Patent number: 11390627Abstract: Compounds and compositions for use as starting materials or intermediate materials in the preparation of opioids including, e.g., oxycodone base and/or an oxycodone salt; processes for preparing these compounds and compositions; uses of these compounds and compositions in the preparation of APIs and pharmaceutical dosage forms; and uses of said APIs and pharmaceutical dosage forms in the treatment of medical conditions.Type: GrantFiled: September 8, 2020Date of Patent: July 19, 2022Assignee: RHODES TECHNOLOGIESInventors: Stuart James Gebbie, Joshua R. Giguere, Keith Mccarthy, Lonn S. Rider
-
Patent number: 11384091Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: GrantFiled: June 12, 2020Date of Patent: July 12, 2022Assignees: Purdue Pharma L.P., Purdue Pharmaceuticals L.P., Rhodes TechnologiesInventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
-
Publication number: 20220041612Abstract: This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R1 is H or CH3, R2 is H or OH, n is 0, 1, 2 or 3, R3 and R4 are independently H or optionally substituted C1-C4 alkyl, or when n is 0, then R3 and R4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C1-C4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.Type: ApplicationFiled: August 20, 2021Publication date: February 10, 2022Applicant: Rhodes TechnologiesInventors: Robert J. KUPPER, Raymond C. GLOWAKY
-
Publication number: 20210299046Abstract: The invention provides emulsion compositions comprising at least one cannabinoid compound, and methods for making the same. The emulsion compositions are stable, well tolerated and are capable of delivering therapeutically effective amounts of cannabiniods to target sites, including sites on the surface of and/or within an eye. Also provided are methods of using the compositions to provide ocular neuroprotection and/or to treat ophthalmic conditions such as glaucoma.Type: ApplicationFiled: August 10, 2018Publication date: September 30, 2021Applicant: Rhodes TechnologiesInventors: Ping CHANG, Zhenze HU, Yuanyuan TAO
-
Patent number: 11130765Abstract: This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R1 is H or CH3, R2 is H or OH, n is 0, 1, 2 or 3, R3 and R4 are independently H or optionally substituted C1-C4 alkyl, or when n is 0, then R3 and R4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C1-C4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.Type: GrantFiled: April 28, 2020Date of Patent: September 28, 2021Assignee: Rhodes TechnologiesInventors: Robert J. Kupper, Raymond C. Glowaky
-
Patent number: 11091496Abstract: This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R1 is H or CH3, R2 is H or OH, n is 0, 1, 2 or 3, R3 and R4 are independently or optionally substituted C1-C4 alkyl, or when n is 0, then R3 and R4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C1-C4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.Type: GrantFiled: July 22, 2019Date of Patent: August 17, 2021Assignee: RHODES TECHNOLOGIESInventors: Robert J. Kupper, Raymond C. Glowaky
-
Publication number: 20210236456Abstract: The present disclosure provides pharmaceutical compositions comprising a cannabinoid, and dosage forms comprising same, for oral delivery, such as sublingual or buccal delivery. The compositions of the present disclosure are substantially homogeneous and remain stable and monophasic upon storage. Also provided are methods of using the compositions for pain management and to treat various diseases and conditions, including dementia, sleep disorders, movement disorders, mental disorders, and multiple sclerosis.Type: ApplicationFiled: May 10, 2019Publication date: August 5, 2021Applicant: RHODES TECHNOLOGIESInventors: Ping CHANG, Marc BROWN, Charles EVANS
-
Publication number: 20210198268Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: ApplicationFiled: March 15, 2021Publication date: July 1, 2021Applicants: Purdue Pharma L.P., Purdue Pharmaceuticals L.P., Rhodes TechnologiesInventors: Robert CHAPMAN, Lonn S. RIDER, Qi HONG, Robert KUPPER, Donald J. KYLE
-
Patent number: 10988480Abstract: This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R1 is H or CH3, R2 is H or OH, n is 0, 1, 2 or 3, R3 and R4 are independently H or optionally substituted C1-C4 alkyl, or when n is 0, then R3 and R4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C1-C4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.Type: GrantFiled: May 4, 2016Date of Patent: April 27, 2021Assignee: Rhodes TechnologiesInventors: Robert J. Kupper, Raymond C. Glowaky